August 27, 2024 02:09 PM EDT

Widening GLP-1 coverage could cost Medicare almost $150B annually, study finds

Max Bayer

Pharma Reporter

As Congress considers widening Medicare’s coverage of the burgeoning class of weight loss medications, a new study says further expansion of eligible patients into new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Widening GLP-1 coverage could cost Medicare almost $150B annually, study finds

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Post-Hoc: Big promises built Moderna. They might also be its undoing

After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penalty

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Doug Williams returns with a ‘FIT’ bet on CAR-Ts; Biogen appoints Mene Pangalos to board

Widen­ing GLP-1 cov­er­age could cost Medicare al­most $150B an­nu­al­ly, study finds

Pharma Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Widening GLP-1 coverage could cost Medicare almost $150B annually, study finds